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Abstract
Introduction:  Hyperinsulinism is the most common cause of recurrent and persistent
hypoglycemia in infancy and childhood. Causes can include nesidioblastosis, pancreatic islet cell
tumors such as insulinoma, and associations with multiple endocrine neoplasia syndromes.
Although new, improved imaging techniques have allowed for more precise preoperative
localization of insulinomas, the differentiation of nesidioblastosis and insulinoma, particularly in
children, can be challenging. To improve intraoperative localization and confirmation of successful
resection of insulinoma, a novel hormonal assay, the rapid intraoperative insulin assay, is reported
for the first time in a pediatric patient. This intraoperative radioimmunoassay for insulin yields
results within several minutes and confirms complete resection of insulinoma.
Case description: We present a case of pancreatic insulinoma in a child with symptoms of severe
hypoglycemia, causing seizures. The insulinoma was enucleated laparoscopically, and rapid intra-
operative insulin assay used to determine the success of the procedure.
Discussion and evaluation: This rapid intra-operative test provides a valuable adjunct for
determining complete excision in complicated cases of recurrent or questionable insulinoma.
Although not a common problem, for pediatric patients in whom the diagnosis is not clear, this test
may provide a novel approach to confirming disease.
Conclusion:  We propose the use of this assay in facilitating intra-operative resection and
confirmation of complete excision in pediatric patients. This population may especially benefit from
this novel assay to confirm complete resection and to differentiate multiple etiologies of
hyperinsulinism.
Background
Hyperinsulinism is the most common cause of recurrent
and persistent hypoglycemia in infancy and childhood
[1]. Causes can include nesidioblastosis, pancreatic islet
cell tumors such as insulinoma, and associations with
multiple endocrine neoplasia syndromes. Pancreatic islet
cell tumors have an annual incidence of 1 in 1,000,000,
with insulinoma being the most common type, account-
ing for 70% to 80% of all pancreatic endocrine tumors.
Peak incidence is in the third and fifth decades of life, but
it can occur in all age groups. These tumors are usually sol-
itary, benign, and diagnosed while still small because of
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clinical presentation of uncontrollable hypoglycemia [2].
Insulinoma is equally distributed throughout the whole
pancreatic gland. Preoperative localization is sometimes
challenging, with up to 64% not localized at laparotomy
[3]. New improved imaging techniques have allowed for
more precise preoperative localization. Noninvasive
imaging modalities include transabdominal ultrasound
(US), computed tomography (CT), and magnetic reso-
nance imaging (MRI). While transabdominal US shows
30% sensitivity in detecting a tumor, conventional CT
provides 73% sensitivity [4,5]. Invasive imaging proce-
dures such as angiography and transhepatic venous hor-
mone sampling are more accurate in detecting tumor, but
they are more expensive and depend on the experience of
the person performing the study. Sensitivity with angiog-
raphy is 35% to 65%, and 77% to 100% with transhepatic
portal venous sampling [5,6]. Selective arterial calcium
stimulation and hepatic venous sampling is another inva-
sive method, with a sensitivity of nearly 100% [6,7].
Endoscopic ultrasound (EUS) is the procedure of choice
for tumor localization. With 2–3-mm resolution, EUS can
be used with radial (diagnostic) or linear (for fine needle
aspiration) echoendoscope and allows continuous imag-
ing technique. Accuracy of EUS is 88% and, in combina-
tion with biphasic helical CT, increases to 97%.
Intraoperative EUS can successfully localize tumors in
90% of cases [8] and can determine tumor size and inva-
sion into the duodenum as well as vascular invasion (por-
tal vein, small mesenteric artery, splenic vein) metastasis
into the regional lymph nodes. It may distinguish nonma-
lignant lesions from pancreatic carcinomas.
Even with these diagnostic studies, localization of insuli-
noma can be difficult, and, especially in the child, must be
differentiated from nesidioblastosis. This clinical and
pathologic disease involves hyperplasia of the beta cells of
the pancreas, which leads to persistent hyperinsulinemic
hypoglycemia of infancy (PHHI) and can present in
adults with organic hyperinsulinism [9]. In infants, the
annual incidence is 1 in 50,000 births for the sporadic
form, but may be up to 1 in 2,500 births in certain regions
[10]. Treatment varies significantly, depending on symp-
toms, from medical management with diazoxide and
chlorothiazide, nifedipine, glucagon, and octreotide to
some who require partial or subtotal pancreatectomy
[11]. Surgery, however, results in high rates of pancreatic
endocrine and exocrine insufficiency, with long-term
complications of diabetes mellitus or malnutrition.
To improve intraoperative localization and confirmation
of successful resection, a novel hormonal assay, the rapid
intraoperative insulin assay, has been developed. This
intraoperative radioimmunoassay for insulin yields
results within several minutes and confirms complete
resection of insulinoma. It determines the level of active
insulin molecule in the serum and is checked before
insulinoma enucleation and right after enucleation intra-
operatively. Although there is little guidance as to precise
criteria for gauging success, one proposed protocol is sim-
ilar to that used for quick parathyroid hormone (PTH)
assay (i.e., a 50% drop). When insulin levels drop more
than 50% of baseline within several minutes of insuli-
noma resection, the surgery is considered successful.
Here we present a case of pancreatic insulinoma in a child
with symptoms of severe hypoglycemia, causing seizures.
The insulinoma was enucleated laparoscopically – a well-
accepted technique for appropriately selected lesions [8-
10]. Intraoperative insulin measurements confirmed
complete tumor resection. We aim to demonstrate that for
the pediatric patient, in particular, the rapid intraopera-
tive insulin assay has many advantages for the surgeon in
confirming successful resection of insulin-producing
tumors.
Case presentation
The patient is a 13-year-old male with no prior medical
history who presented in December of 2004 with a gen-
eral tonic-clonic seizure after a basketball game. Blood
glucose was 33 mg/dL. Workup was delayed. He had a sec-
ond seizure in late January 2005 associated with a glucose
level less than 40 mg/dL. At that time the C-peptide level
was 8.1 U/dL. The patient was admitted for a 72-hour
inpatient fast in late March 2005, and had a seizure at
hour 18 of the fast. His glucose was 33 mg/dL with an
insulin level equal to 21 U/dL, confirming the diagnosis
of insulinoma. CT scanning and MRI were performed and
demonstrated a 1.8 cm mass in the neck of the pancreas.
After several additional seizures he was referred to Colum-
bia Presbyterian Hospital for evaluation and admitted
from the office for glucose monitoring and preoperative
preparation. The patient underwent intraoperative US fol-
lowed by laparoscopic enucleation of a pancreatic islet
cell tumor.
Operative procedure
An arterial line was inserted to allow frequent glucose test-
ing during the operative procedure. The patient's baseline
glucose level was 54 mg/dL with a baseline insulin level of
125 U/dL (normal 10–86 U/dL). Glucose solution was
administered intraoperatively to maintain a blood glu-
cose level greater than 100 mg/dL. After induction of gen-
eral anesthesia and positioning in the modified lithotomy
position, the abdomen was insufflated to 15 mm Hg with
CO2. Two 12 mm trocars and three 5 mm trocars were
inserted and the lesser sac entered through the omentum,
preserving the right gastroepiploic vessels to expose the
anterior surface of the pancreas. The inferior aspect of the
pancreas was then mobilized to allow inspection of the
posterior surface. The splenic vein was clearly identifiedAnnals of Surgical Innovation and Research 2007, 1:6 http://www.asir-journal.com/content/1/1/6
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and dissected. The pancreas was dissected medially and a
space posterior to the pancreas and anterior to the portal
vein was developed. Laparoscopic US identified a hypoe-
choic mass in the neck of the pancreas, which was enucle-
ated using a combination of blunt and sharp dissection
techniques. The lesion was placed in a retrieval sac and
extracted.
Intraoperative insulin levels of 172 U/dL were measured
after initial identification of the insulinoma. At 5 and 10
minutes postexcision, values dropped to 87 U/dL and 68
U/dL, respectively, demonstrating complete resection.
Total operating time was 120 minutes. Postoperatively,
the patient's blood glucose increased to 130 mg/dL.
The patient developed a pancreatic fistula postoperatively,
which was initially controlled via drainage catheter and
conservative measures, but ultimately required re-explora-
tion with a distal pancreatectomy and splenectomy. The
patient subsequently recovered without complication and
final pathology showed a 1.4 × 1.2 × 0.9 cm, well-differ-
entiated, intermediate grade insulinoma.
Rapid insulin assay
To determine insulin levels intraoperatively, we used the
STAT-IntraOperative-System (Future Diagnostics, Arling-
ton, MA). This is a chemiluminescence immunoassay for
the quantitative determination of insulin levels in human
serum and EDTA plasma. The assay uses two monoclonal
antibodies against insulin. Patient samples are introduced
into wells and incubated for 7 minutes. The washed wells
are then placed into the STAT-Read, which calculates insu-
lin levels by measuring emissions of light in relative light
units. The time between obtaining a blood sample and
reading a result is under 12 minutes.
Discussion and evaluation
This rapid intraoperative test gives us a valuable adjunct
for determining complete excision in complicated cases of
recurrent or questionable insulinoma. Although not a
common problem, for patients with an uncertain diagno-
sis, this test may provide a novel approach to confirma-
tion. This is especially the case for the pediatric patient. In
this report, we highlight the utility of the rapid intraoper-
ative insulin assay as an effective and unique method to
confirm curative resection of insulinoma in the pediatric
patient, a population where other hyperinsulin-produc-
ing conditions, such as nesidioblastosis, must be consid-
ered as well. In children, the etiology of hyperinsulinism
can be a diagnostic challenge. This assay may represent
particular utility intraoperatively to confirm curative
resection.
Rapid determination of insulin levels with detection of C-
peptide is a new modality for diagnosing insulinoma. C-
peptide is a 31 amino acid fragment, which is split from
the proinsulin molecule to form bioactive insulin in the
serum. The analysis is performed by radioimmunoassay
and can be done using serum from peripheral blood in a
rapid time period. Insulin has a short serum half-life of
about 5 minutes; 50% is cleared by the liver and 30% by
the kidneys. Several authors have reported the use of intra-
operative insulin monitoring during resection of insulino-
mas in adults, in an attempt to improve intraoperative
resection and outcome [15-19]. Although intraoperative
assays for parathyroidectomy are well established and
available in many centers – they are currently the most
widely used intraoperative means for hormone measure-
ment in the United States – the rapid insulin assay is more
complicated, is not as widely available, and requires a
dedicated team in order to ensure reproducibility and reli-
ability. This assay is a valuable technique that, when per-
formed well, can serve as a useful adjunct to the
management and operative resection of patients with
known or suspected insulinoma. Our goal is to raise
awareness regarding this technique and potential applica-
tions that may be useful to the surgeon.
Treatment of insulinoma is by surgical resection [2,12].
However, the surgeon may not know preoperatively if the
insulinoma is single or multiple or present in a back-
ground of islet cell hyperplasia. To answer these ques-
tions, the rapid intraoperative serum insulin assay may be
useful. In this case report we have presented a child with
an insulinoma for whom intraoperative insulin measure-
ments determined completeness of excision with subse-
quent cure. Postoperatively, the patient remained
normoglycemic and all biochemical parameters returned
to normal.
Conclusion
In conclusion, we present a confirmatory case demon-
strating the utility of the rapid intraoperative insulin assay
in facilitating intraoperative resection and confirmation
of complete excision of insulinoma for the first time in a
pediatric patient. This population may especially benefit
from this novel assay to confirm complete resection and
to differentiate multiple etiologies of hyperinsulinism in
the pediatric population.
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